ACAD ACADIA Pharmaceuticals Inc. Stock Quote

ACAD [NASD]

Index	-	P/E	-	EPS (ttm)	-1.79	Insider Own	0.10%	Shs Outstand	159.28M	Perf Week	0.24%
Market Cap	3.45B	Forward P/E	-	EPS next Y	-1.24	Insider Trans	-46.98%	Shs Float	158.33M	Perf Month	-29.04%
Income	-281.60M	PEG	-	EPS next Q	-0.54	Inst Own	95.00%	Short Float	4.43%	Perf Quarter	-60.28%
Sales	441.80M	P/S	7.82	EPS this Y	-12.00%	Inst Trans	-1.23%	Short Ratio	3.00	Perf Half Y	-50.65%
Book/sh	3.94	P/B	5.40	EPS next Y	33.20%	ROA	-36.50%	Target Price	29.44	Perf Year	-52.64%
Cash/sh	3.89	P/C	5.47	EPS next 5Y	25.00%	ROE	-43.60%	52W Range	20.12 - 58.72	Perf YTD	-60.19%
Dividend	-	P/FCF	-	EPS past 5Y	-1.80%	ROI	-45.80%	52W High	-63.76%	Beta	0.79
Dividend %	-	Quick Ratio	6.70	Sales past 5Y	491.50%	Gross Margin	95.30%	52W Low	5.77%	ATR	2.03
Employees	601	Current Ratio	6.80	Sales Q/Q	23.10%	Oper. Margin	-64.90%	RSI (14)	28.45	Volatility	3.78% 4.68%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-22.20%	Profit Margin	-63.70%	Rel Volume	1.21	Prev Close	20.60
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Feb 24 AMC	Payout	-	Avg Volume	2.34M	Price	21.28
Recom	2.50	SMA20	-12.67%	SMA50	-42.69%	SMA200	-52.40%	Volume	2,816,810	Change	3.30%

Apr-07-21

Downgrade

H.C. Wainwright

Buy → Neutral

$43 → $18

Apr-06-21

Downgrade

Mizuho

Buy → Neutral

$37 → $25

Apr-06-21

Downgrade

Jefferies

Buy → Hold

$40 → $21

Apr-06-21

Downgrade

Goldman

Buy → Neutral

$73 → $25

Apr-06-21

Downgrade

Canaccord Genuity

Buy → Hold

$40 → $26

Apr-05-21

Downgrade

Raymond James

Outperform → Mkt Perform

Mar-10-21

Downgrade

BofA Securities

Buy → Neutral

Mar-09-21

Reiterated

H.C. Wainwright

Buy

$60 → $43

Mar-09-21

Downgrade

Stifel

Buy → Hold

$68 → $27

Mar-09-21

Downgrade

Raymond James

Strong Buy → Outperform

$65 → $35

Mar-09-21

Downgrade

Guggenheim

Buy → Neutral

Mar-09-21

Downgrade

Citigroup

Buy → Neutral

$66 → $35

Dec-16-20

Initiated

Mizuho

Buy

$69

Nov-16-20

Upgrade

Raymond James

Outperform → Strong Buy

$65

Aug-25-20

Initiated

Raymond James

Outperform

$65

Aug-20-20

Initiated

Morgan Stanley

Overweight

$55

Jul-07-20

Upgrade

Stifel

Hold → Buy

$41 → $71

Apr-16-20

Initiated

Jefferies

Buy

$60

Mar-31-20

Upgrade

Goldman

Neutral → Buy

$45 → $72

Mar-06-20

Initiated

Citigroup

Buy

$69

Apr-14-21 05:05PM	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact Its Attorneys, Firm Investigating ACAD for Possible Securities Law Violations Newsfile
10:00AM	SHAREHOLDER ALERT: Acadia Pharmaceuticals Inc. (ACAD) Investigated for Possible Securities Laws Violations by Labaton Sucharow; Investors Should Contact the Firm ACCESSWIRE
Apr-13-21 06:50PM	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Updates ACAD, UI Investors on Securities Fraud Investigations, Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Apr-12-21 08:30AM	Acadia Pharmaceuticals Cannot Catch a Break With Quant Downgrade TheStreet.com
Apr-09-21 07:00PM	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Updates ACAD, UI Investors on Securities Fraud Investigations, Encourages Investors with Losses to Contact the Firm ACCESSWIRE
10:45AM	SHAREHOLDER ALERT: Acadia Pharmaceuticals Inc. (ACAD) Investigated for Possible Securities Laws Violations by Labaton Sucharow; Investors Should Contact the Firm ACCESSWIRE
Apr-08-21 04:20PM	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact Its Attorneys, Firm Investigation ACAD for Possible Securities Law Violations Newsfile
11:30AM	SHAREHOLDER ALERT: Acadia Pharmaceuticals Inc. (ACAD) Investigated for Possible Securities Laws Violations by Labaton Sucharow; Investors Should Contact the Firm ACCESSWIRE
Apr-07-21 04:34PM	Biotech Stock Roundup: ACAD Down on CRL, EBS Gets Additional Order & Other Updates Zacks
03:13PM	Biotech Stock Roundup: ACAD Down on CRL, EBS Gets Additional Order & Other Updates Zacks
01:30PM	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Updates ACAD, DOX, UI Investors on Securities Fraud Investigations, Encourages Investors with Losses to Contact the Firm ACCESSWIRE
10:20AM	SHAREHOLDER ALERT: Acadia Pharmaceuticals Inc. (ACAD) Investigated for Possible Securities Laws Violations by Labaton Sucharow; Investors Should Contact the Firm ACCESSWIRE
Apr-06-21 07:48PM	Is Acadia a Buy Following the FDAs CRL? J.P. Morgan Says Yes TipRanks
05:36PM	After FDA Rejects Acadia Dementia Drug, Analysts Lament Lack Of Near-term Stock Drivers Benzinga
03:39PM	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Acadia Pharmaceuticals (ACAD) For Possible Securities Law Violations, Encourages Investors with Losses to Contact Its Attorneys GlobeNewswire
10:45AM	SHAREHOLDER ALERT: Acadia Pharmaceuticals Inc. (ACAD) Investigated for Possible Securities Laws Violations by Labaton Sucharow; Investors Should Contact the Firm ACCESSWIRE
09:05AM	ACADIA (ACAD) Gets CRL From FDA for Nuplazid sNDA, Shares Down Zacks
08:04AM	The Daily Biotech Pulse: Illumina Lights Up, Cara Soars On Index Inclusion, Novavax Starts Crossover Vaccine Study, Turning Point Data Readout Benzinga
04:55AM	Ademi LLP Investigates Claims of Securities Fraud against Acadia Pharmaceuticals Inc. PR Newswire
Apr-05-21 09:00PM	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Acadia Pharmaceuticals (ACAD) For Possible Securities Law Violations, Encourages Investors with Losses to Contact Its Attorneys PR Newswire -17.23%
04:11PM	Acadia Stock Crashes After FDA Rejects Key Drug Analyst Sees Huge Delay Investor's Business Daily
03:30PM	SHAREHOLDER ALERT: Acadia Pharmaceuticals Inc. (ACAD) Investigated for Possible Securities Laws Violations by Labaton Sucharow; Investors Should Contact the Firm ACCESSWIRE
11:32AM	FDA Rejects Acadias Supplemental New Drug Application For NUPLAZID; Shares Plunge SmarterAnalyst
10:30AM	SHAREHOLDER ALERT: Acadia Pharmaceuticals Inc. (ACAD) Investigated for Possible Securities Laws Violations by Labaton Sucharow; Investors Should Contact the Firm ACCESSWIRE
07:43AM	Acadia Pharmaceuticals: a Tough Pill to Swallow TheStreet.com
07:22AM	Acadia Stock Drops After FDA CRL For Pimavanserin Application In Hallucinations and Dementia-Related Psychosis Benzinga
06:30AM	Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis Business Wire
Mar-30-21 01:23PM	Replay: Investing in Alzheimers Treatment Jupiter Orphan Therapeutics CEO Joins Fireside Chat IPO-Edge.com
Mar-29-21 12:07PM	Is ACADIA Pharmaceuticals (ACAD) Stock A Buy or Sell? Insider Monkey
Mar-26-21 11:31AM	Why Is Acadia (ACAD) Down 45% Since Last Earnings Report? Zacks
Mar-24-21 02:34PM	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Acadia Pharmaceuticals (ACAD) For Possible Securities Law Violations, Encourages Investors with Losses to Contact Its Attorneys GlobeNewswire
09:00AM	Kaskela Law LLC Announces Investigation of Acadia Pharmaceuticals Inc. (ACAD) and Encourages Long-Term ACAD Stockholders to Contact the Firm GlobeNewswire
07:28AM	Moving Average Crossover Alert: ACADIA Pharma Zacks
Mar-23-21 01:53PM	Investing in Alzheimers Treatment: Join Jupiter Orphan Therapeutics for Fireside Chat March 30 IPO-Edge.com
Mar-15-21 05:14PM	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Acadia Pharmaceuticals (ACAD) For Possible Securities Law Violations, Encourages Investors with Losses to Contact Its Attorneys Newsfile +10.91%
Mar-14-21 08:24PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD Newsfile
Mar-12-21 01:15PM	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Continues Investigation into Acadia Pharmaceuticals (ACAD) For Possible Securities Law Violations, Encourages Investors with Losses to Contact Its Attorneys ACCESSWIRE
06:05AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD CNW Group
Mar-10-21 04:02PM	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Acadia Pharmaceuticals (ACAD) For Possible Securities Law Violations, Encourages Investors with Losses to Contact Its Attorneys GlobeNewswire +7.47%
03:14PM	Biotech Stock Roundup: AMGN's Acquisition, ACAD's Regulatory Update & More Zacks
12:34PM	Acadia Pharmaceuticals: Is Potential Nuplazid Delay A Sign Of Trouble Or An Opportunity? TipRanks
12:00PM	Bronstein, Gewirtz & Grossman, LLC Announces Investigation of ACADIA Pharmaceuticals Inc. (ACAD) and Encourages Investors to Contact the Firm ACCESSWIRE
02:50AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD PR Newswire
Mar-09-21 10:39PM	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Acadia Pharmaceuticals (ACAD) For Possible Securities Law Violations, Encourages Investors with Losses to Contact Its Attorneys PR Newswire -45.35%
07:41PM	Is ACADIA Still a Buy Following FDA Setback? Analyst Weighs In TipRanks
04:19PM	Acadia Stock: Why It Could Be Facing A Year-Long Delay Or Rejection Investor's Business Daily
12:00PM	SHAREHOLDER ALERT: Acadia Pharmaceuticals Inc. Investigated for Possible Securities Laws Violations by Block & Leviton LLP; Investors Should Contact the Firm Newsfile
10:28AM	Looking Into ACADIA Pharmaceuticals's Return On Capital Employed Benzinga
09:20AM	Why Acadia Pharmaceuticals Stock Is Crashing Today Motley Fool
09:11AM	ACADIA (ACAD) Falls as FDA Finds Deficiencies in Nuplazid sNDA Zacks
08:37AM	Acadia Pharmaceuticals stock leads premarket losers after FDA finds undisclosed 'deficiencies' in NDA MarketWatch
08:17AM	Acadia Shares Plummet After FDA Finds Flaws in Drug Application Barrons.com
Mar-08-21 07:16PM	SHAREHOLDER ALERT: Acadia Pharmaceuticals Inc. Investigated for Possible Securities Laws Violations by Block & Leviton LLP; Investors Should Contact the Firm ACCESSWIRE -6.53%
04:05PM	Acadia Pharmaceuticals Provides Regulatory Update on Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis Business Wire
Feb-25-21 09:17AM	ROCE Insights For ACADIA Pharmaceuticals Benzinga
Feb-24-21 04:46PM	Recap: ACADIA Pharmaceuticals Q4 Earnings Benzinga
04:05PM	Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results Business Wire
02:30PM	ACADIA Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Feb-23-21 10:11AM	A Preview Of ACADIA Pharmaceuticals's Earnings Benzinga
Feb-22-21 11:10PM	Announcing: ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Increased An Energizing 191% In The Last Five Years Simply Wall St.
Feb-19-21 09:00AM	Acadia Pharmaceuticals Recognizes National Caregivers Day with Launch of MoreThanMemoryLoss.com Business Wire
Feb-18-21 09:00AM	Acadia Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire
Feb-10-21 09:00AM	Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021 Business Wire
Jan-27-21 04:05PM	Acadia Pharmaceuticals Announces Commercial Leadership Change Business Wire -5.81%
Jan-11-21 01:31PM	Shuman Glenn & Stecker Investigates Acadia Pharmaceuticals, Inc. Business Wire
Dec-22-20 09:00AM	Acadia Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021 Business Wire
Dec-15-20 02:34PM	Is ACAD A Good Stock To Buy Now? Insider Monkey
Dec-04-20 11:31AM	Why Is Acadia (ACAD) Up 9.7% Since Last Earnings Report? Zacks
Nov-24-20 11:21PM	ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Shift From Loss To Profit Simply Wall St.
Nov-11-20 03:15AM	These 23 stocks and ETFs will benefit from the 6 most important changes for stock-market investors under Biden MarketWatch
Nov-10-20 09:00AM	Acadia Pharmaceuticals to Present at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020 Business Wire
Nov-05-20 12:45PM	ACADIA (ACAD) Q3 Earnings Miss, Nuplazid Drives Revenues Y/Y Zacks
06:07AM	What's Behind Acadia Pharmaceuticals' Mixed Q3 Results Motley Fool
Nov-04-20 05:55PM	Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Tops Revenue Estimates Zacks +5.43%
04:05PM	Acadia Pharmaceuticals Reports Third Quarter 2020 Financial Results Business Wire
02:30PM	ACADIA Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Oct-28-20 12:32PM	Earnings Preview: Acadia Pharmaceuticals (ACAD) Q3 Earnings Expected to Decline Zacks
Oct-26-20 10:02PM	Were Hedge Funds Wrong About Embracing ACADIA Pharmaceuticals Inc. (ACAD)? Insider Monkey
09:00AM	Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the 13th Clinical Trials on Alzheimer's Disease (CTAD) Conference Business Wire
Oct-21-20 04:05PM	Acadia Pharmaceuticals to Announce Third Quarter 2020 Financial Results on November 4, 2020 Business Wire
Oct-14-20 04:05PM	The Lewy Body Dementia Association and Acadia Pharmaceuticals to Release Educational Version of the Highly Acclaimed Robin Williams Documentary, "Robins Wish" Business Wire
Oct-01-20 09:00AM	Acadia Pharmaceuticals Appoints Elizabeth Garofalo, M.D. to Board of Directors Business Wire
Sep-07-20 05:15PM	Hedge Funds Never Been This Bullish On ACADIA Pharmaceuticals Inc. (ACAD) Insider Monkey
Sep-05-20 08:47AM	(ACAD) Alert: Johnson Fistel Announces Shareholder Class Action Against ACADIA Pharmaceuticals Survives Motion to Dismiss; Should Management be Held Accountable for Investors Losses? PR Newswire
Sep-04-20 11:31AM	Acadia (ACAD) Down 12% Since Last Earnings Report: Can It Rebound? Zacks
Sep-02-20 09:00AM	ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire
Aug-31-20 09:00AM	ACADIA Pharmaceuticals Appoints Gudarz Davar, M.D., as Executive Vice President and Head of Research and Development Business Wire
Aug-26-20 10:44PM	5 Biotech Stocks That Could Be Worth a Look Barrons.com
01:01PM	ACADIA Acquires CerSci Therapeutics to Boost Pain Portfolio Zacks
Aug-25-20 09:35AM	Benzinga's Top Upgrades, Downgrades For August 25, 2020 Benzinga
09:00AM	ACADIA Pharmaceuticals Acquires CerSci Therapeutics, Adds Novel Pain Program to Portfolio Business Wire
Aug-24-20 07:08AM	What Does ACADIA Pharmaceuticals' (NASDAQ:ACAD) CEO Pay Reveal? Simply Wall St.
Aug-23-20 11:33AM	Morgan Stanley Is Getting Bullish About Biotech; Here Are 2 Stocks to Buy TipRanks
Aug-20-20 09:51AM	Benzinga's Top Upgrades, Downgrades For August 20, 2020 Benzinga
Aug-12-20 09:00AM	ACADIA Pharmaceuticals to Present at The JMP Securities CNS Forum on August 19, 2020 Business Wire
Aug-06-20 01:19PM	ACADIA (ACAD) Q2 Earnings Surpass, Nuplazid Drives Sales Zacks
Aug-05-20 06:25PM	Acadia Pharmaceuticals (ACAD) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:05PM	ACADIA Pharmaceuticals Reports Second Quarter 2020 Financial Results Business Wire
Jul-31-20 08:00PM	SHAREHOLDER ALERT: Barr Law Group Investigating the Officers and Directors of ACADIA Pharmaceuticals Inc. (ACAD) Newsfile
Jul-30-20 03:37PM	SHAREHOLDER ALERT: Stephens & Stephens LLP Investigating the Officers and Directors of ACADIA Pharmaceuticals Inc. (ACAD) Business Wire

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KIM AUSTIN D.	EVP & General Counsel	Feb 04	Sale	50.61	2,107	106,635	9,911	Feb 08 09:00 PM
Stankovic Srdjan R.	President	Feb 04	Sale	50.61	8,429	426,592	31,049	Feb 08 09:00 PM
DAVIS STEPHEN	CEO	Feb 04	Sale	50.61	14,195	718,409	28,900	Feb 08 09:00 PM
Ridloff Elena	EVP and CFO	Feb 04	Sale	50.61	2,051	103,801	8,340	Feb 08 09:00 PM
Stankovic Srdjan R.	President	Jan 12	Option Exercise	18.12	700	12,684	20,947	Jan 14 07:03 PM
Stankovic Srdjan R.	President	Jan 12	Sale	55.01	700	38,507	20,247	Jan 14 07:03 PM
Stankovic Srdjan R.	President	Jan 08	Option Exercise	27.44	29,733	815,988	49,980	Jan 08 07:28 PM
Stankovic Srdjan R.	President	Jan 08	Sale	55.22	29,733	1,641,832	20,247	Jan 08 07:28 PM
Stankovic Srdjan R.	President	Jan 07	Option Exercise	35.80	61,619	2,205,960	81,866	Jan 08 07:28 PM
Stankovic Srdjan R.	President	Jan 07	Sale	55.12	61,619	3,396,187	20,247	Jan 08 07:28 PM
YANG MICHAEL J.	EVP and CCO	Jan 06	Sale	53.34	1,120	59,741	8,059	Jan 08 07:31 PM
KIM AUSTIN D.	EVP & General Counsel	Jan 06	Sale	53.34	678	36,165	5,518	Jan 08 07:30 PM
Ridloff Elena	EVP and CFO	Jan 06	Sale	53.34	1,016	54,193	3,901	Jan 08 07:29 PM
Stankovic Srdjan R.	President	Jan 06	Sale	53.34	1,725	92,012	20,247	Jan 08 07:28 PM
DAVIS STEPHEN	CEO	Jan 06	Sale	53.34	3,484	185,837	24,482	Jan 08 07:28 PM
Stankovic Srdjan R.	President	Nov 20	Sale	53.50	2,728	145,948	16,528	Nov 20 09:29 PM
KIM AUSTIN D.	EVP & General Counsel	Oct 27	Option Exercise	17.58	8,750	153,825	12,601	Oct 29 04:12 PM
KIM AUSTIN D.	EVP & General Counsel	Oct 27	Sale	45.10	8,750	394,636	3,851	Oct 29 04:12 PM
YANG MICHAEL J.	EVP and CCO	Oct 16	Sale	42.56	1,247	53,072	6,457	Oct 19 05:27 PM
Stankovic Srdjan R.	President	Oct 16	Sale	42.56	1,297	55,200	13,006	Oct 19 05:26 PM
DAVIS STEPHEN	CEO	Oct 16	Sale	42.56	2,960	125,978	14,786	Oct 19 05:25 PM
YANG MICHAEL J.	EVP and CCO	Jul 07	Option Exercise	23.00	27,250	626,770	32,454	Jul 09 06:26 PM
YANG MICHAEL J.	EVP and CCO	Jul 07	Sale	56.25	27,250	1,532,786	5,204	Jul 09 06:26 PM
Stankovic Srdjan R.	President	Jun 19	Option Exercise	18.12	16,452	298,110	27,786	Jun 19 06:55 PM
Stankovic Srdjan R.	President	Jun 19	Sale	50.12	16,452	824,515	11,334	Jun 19 06:55 PM
Stankovic Srdjan R.	President	Jun 18	Option Exercise	18.81	65,843	1,238,697	77,177	Jun 19 06:55 PM
Stankovic Srdjan R.	President	Jun 18	Sale	50.01	65,843	3,292,729	11,334	Jun 19 06:55 PM
DAVIS STEPHEN	CEO	May 14	Option Exercise	19.65	88,542	1,739,850	100,351	May 15 07:11 PM
DAVIS STEPHEN	CEO	May 14	Sale	45.62	88,542	4,039,105	11,809	May 15 07:11 PM
DAVIS STEPHEN	CEO	May 13	Option Exercise	19.65	111,458	2,190,150	123,267	May 15 07:11 PM
DAVIS STEPHEN	CEO	May 13	Sale	46.35	111,458	5,165,587	11,809	May 15 07:11 PM
Daly James M	Director	May 11	Option Exercise	26.39	26,250	692,700	26,250	May 13 06:00 PM
Daly James M	Director	May 11	Sale	51.13	26,250	1,342,178	0	May 13 06:00 PM
Stankovic Srdjan R.	President	Apr 30	Sale	49.21	4,308	211,997	11,334	May 01 06:00 PM
Ridloff Elena	EVP and CFO	Apr 30	Sale	49.22	1,050	51,681	2,195	May 01 06:00 PM
DAVIS STEPHEN	CEO	Apr 30	Sale	49.21	6,770	333,152	11,809	May 01 06:00 PM
YANG MICHAEL J.	EVP and CCO	Apr 30	Sale	49.21	1,501	73,864	5,204	May 01 06:00 PM
KIM AUSTIN D.	EVP & General Counsel	Apr 30	Sale	49.22	1,072	52,764	2,441	May 01 06:00 PM
Ridloff Elena	EVP and CFO	Apr 29	Option Exercise	25.12	10,000	251,200	10,000	May 01 06:00 PM
Ridloff Elena	EVP and CFO	Apr 29	Sale	50.74	10,000	507,353	0	May 01 06:00 PM
Stankovic Srdjan R.	President	Apr 23	Option Exercise	20.67	18,949	391,704	24,976	Apr 24 06:00 PM
Stankovic Srdjan R.	President	Apr 23	Sale	50.07	18,949	948,729	6,027	Apr 24 06:00 PM
Stankovic Srdjan R.	President	Apr 22	Option Exercise	19.77	54,019	1,067,956	60,046	Apr 22 06:30 PM
Stankovic Srdjan R.	President	Apr 22	Sale	50.02	54,019	2,701,906	6,027	Apr 22 06:30 PM
Stankovic Srdjan R.	President	Apr 20	Option Exercise	19.65	100,000	1,965,000	106,027	Apr 22 06:30 PM
Stankovic Srdjan R.	President	Apr 20	Sale	50.15	100,000	5,015,450	6,027	Apr 22 06:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience